Adjuvant therapy for gastric cancer: What have we learned since INT0116?

Table 1 Randomized clinical trials comparing adjuvant chemoradiotherapy vs chemotherapy

Ref.	Treatment	n	D	DFS	OS	Toxicities G3-G4
Park et al[17]	XP vs XP/XRT/XP	458	D2	0.74 (0.52-1.05)	1.13 (0.77-1.64)	N 12%, V 3% in both groups
Kim et al[19]	FL/FL + RT/FL vs FL	90	D2	60.9% vs 50.0%	65.2% vs 54.6%	Hem 25%, GI 11.4% vs Hem 19.6%, GI 17.4%
Zhu et al[20]	FL/FL + IMRT/FL vs FL	404	D2	1.35 (1.03-1.78)	1.24 (0.94-1.65)	Leuco 7.5%, N 2.7% vs Leuco 7.3%, N 0%

D: Lymphadenectomy; DFS: Disease-free survival; OS: Overall survival; XP: Capecitabine + Cisplatin; FL: 5-Fluorouracil + Leucovorin; Hem: Hematological; GI: Gastrointestinal; N: Nausea; V: Vomiting; Leuco: Leucopenia.